We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

44 hedge funds and large institutions have $8.59M invested in Evofem Biosciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more call options, than puts

Call options by funds: $3.83M | Put options by funds: $1.18M

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

13% less capital invested

Capital invested by funds: $9.84M → $8.59M (-$1.26M)

35% less funds holding

Funds holding: 68 → 44 (-24)

71% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 34

Holders
44
Holders Change
-24
Holders Change %
-35.29%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
16
Reduced
13
Closed
34
Calls
$3.83M
Puts
$1.18M
Net Calls
+$2.65M
Net Calls Change
+$2.08M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$4.26M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$3.22M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.45M
4
Citigroup
Citigroup
New York
+$1.21M
5
Citadel Advisors
Citadel Advisors
Florida
+$313K

Top Sellers

Rank Fund Capital Flow
1
MCP
Mirador Capital Partners
California
-$955K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$167K
3
JCP
JB Capital Partners
New York
-$118K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$74.4K
5
Group One Trading
Group One Trading
Illinois
-$43.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
WIM
26
Westside Investment Management
California
$2.97K +$15.4K +9,333 +1,399%
IA
27
IFP Advisors
Florida
$2K +$46 +28 +1,400%
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
$1K -$54 -33 -3%
National Bank of Canada
29
National Bank of Canada
Quebec, Canada
$1K -$3 -2 -0.4%
CG
30
Cutler Group
California
$1K -$2 -1 -0.1%
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Quebec, Canada
$35 +$51 +31 New
LTI
32
Laffer Tengler Investments
Tennessee
$16 – – –
MCP
33
Mirador Capital Partners
California
– -$955K -187,179 Closed
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
– -$74.4K -45,113 Closed
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
– -$167K -32,782 Closed
Group One Trading
36
Group One Trading
Illinois
– -$43.6K -26,463 Closed
RC
37
RBF Capital
California
– -$25K -4,637 Closed
Charles Schwab
38
Charles Schwab
California
– -$23K -4,509 Closed
TAM
39
Tocqueville Asset Management
New York
– -$17K -3,404 Closed
DC
40
Davenport & Co
Virginia
– -$13K -2,633 Closed
HighTower Advisors
41
HighTower Advisors
Illinois
– -$12K -2,488 Closed
BCM
42
Bayesian Capital Management
New York
– -$12K -2,393 Closed
Bank of New York Mellon
43
Bank of New York Mellon
New York
– -$11K -2,175 Closed
LPL Financial
44
LPL Financial
California
– -$9K -1,750 Closed
Goldman Sachs
45
Goldman Sachs
New York
– -$8K -1,643 Closed
Victory Capital Management
46
Victory Capital Management
Texas
– -$4K -1,625 Closed
JCP
47
JB Capital Partners
New York
– -$118K -1,546 Closed
HF
48
HRT Financial
New York
– -$6K -1,236 Closed
BSW
49
Buckingham Strategic Wealth
Missouri
– -$6K -1,235 Closed
Renaissance Technologies
50
Renaissance Technologies
New York
– -$6K -1,226 Closed
1
2
3

EVFM Hedge Fund Activity: Q2 2022 in Review

44 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2022, worth a combined $8.59M — down 13% from $9.84M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of EVFM and 10 opened new positions — a net loss of 24 holders — while 13 trimmed existing stakes and 16 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $4.26M. The largest seller was Mirador Capital Partners, exiting entirely with an estimated $955K sold.

  • 44 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2022, down from 68 in Q1 2022.
  • Funds reported $8.59M of Evofem Biosciences, Inc. Common Stock stock for Q2 2022, down 13% quarter-over-quarter.
  • 10 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2022 and 34 closed out, a net change of -24 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2022 was Baker Bros. Advisors, an estimated $4.26M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2022 was Mirador Capital Partners, an estimated $955K sold.

Based on aggregated 13F filings for Q2 2022.